News | September 04, 2025
Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
Subscribe To Our Newsletter & Stay Updated
